Branched worm-like nanoparticles featured with programmed drug release for synergistic castration-resistant prostate cancer therapy
Source abstract
Abstract
Co-delivery systems with programmed release of combined drugs are of great value for combination cancer therapy. However, design of such co-delivery systems for potent synergistic cancer therapy is still a great challenge. In the present work, dimethylcurcumin (DMC) and docetaxel (DTX) co-loaded branched worm-like nanoparticles (NPs) with programmed release of DMC and DTX were developed for potent synergistic castration-resistant prostate cancer (CRPC) therapy. (2-Hydroxypropyl)-β-cyclodextrin-retinoic acid (HP-β-CD-RA) conjugates with different molar ratios of RA to HP-β-CD were synthesized and used for the preparation of DMC and DTX co-loaded NPs. The as-prepared DMC and DTX co-loaded NPs (Dh 170–190 nm) have branched worm-like morphologies, and DMC/DTX@HP-β-CD-RA3.0 NPs show the highest drug loading content and encapsulation efficiency. DMC/DTX@HP-β-CD-RA3.0 NPs exhibit programmed drug release patterns with DTX released much faster than DMC, which could be ascribed to the difference between DMC and DTX in the interaction with HP-β-CD-RA3.0 as analyzed by molecular simulation, phase solubility method, and fluorescence spectra. DMC/DTX@HP-β-CD-RA3.0 NPs exhibit enhanced cellular uptake as compared to DMC/DTX. Mechanism dissection reveals that the cellular uptake of DMC/DTX@HP-β-CD-RA3.0 NPs is energy-dependent in which macropinocytosis and clathrin- and caveolae-independent endocytosis pathways are involved. Benefited from their enhanced cellular uptake and programmed drug release, DMC/DTX@HP-β-CD-RA3.0 NPs exhibit significantly enhanced antitumor effect as compared to DMC/DTX. Such mechanisms for potent synergistic antitumor effect, by enhancing cellular uptake of DMC and DTX together with programmed drug release, may provide new therapeutic options for CRPC.
Source: openaire · Quality: candidate unverified · Source record ↗
Research context
OpenAlex topics: Nanoparticle-Based Drug Delivery · Nanoplatforms for cancer theranostics · Prostate Cancer Treatment and Research
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
References (64)
Show source-provided references
1. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A (2018) Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 68:394–42410.3322/caac.21492 ↗
2. Cioni B, Zwart W, Bergman AM (2018) Androgen receptor moonlighting in the prostate cancer microenvironment. Endocr Relat Cancer 25:R331–R34910.1530/ERC-18-0042 ↗
3. Yap TA, Smith AD, Ferraldeschi R, Al-Lazikani B, Workman P, de Bono JS (2016) Drug discovery in advanced prostate cancer: translating biology into therapy. Nat Rev Drug Discov 15:699–71810.1038/nrd.2016.120 ↗
4. Wadosky KM, Koochekpour S (2016) Molecular mechanisms underlying resistance to androgen deprivation therapy in prostate cancer. Oncotarget 7:64447–6447010.18632/oncotarget.10901 ↗
5. Chen X, Li Q, Liu X et al (2016) Defining a population of stem-like human prostate cancer cells that can generate and propagate castration-resistant prostate cancer. Clin Cancer Res 22:4505–451610.1158/1078-0432.CCR-15-2956 ↗
6. De Maeseneer DJ, Van Praet C, Lumen N, Rottey S (2015) Battling resistance mechanisms in antihormonal prostate cancer treatment: novel agents and combinations. Urol Oncol Semin Orig Investig 33:310–321
7. Nevedomskaya E, Baumgart SJ, Haendler B (2018) Recent advances in prostate cancer treatment and drug discovery. Int J Mol Sci 19:135910.3390/ijms19051359 ↗
8. Barrie SE, Potter GA, Goddard PM, Haynes BP, Dowsett M, Jarman M (1994) Pharmacology of novel steroidal inhibitors of cytochrome P450(17) alpha (17 alpha-hydroxylase/C17-20 lyase). J Steroid Biochem Mol Biol 50:267–27310.1016/0960-0760(94)90131-7 ↗
9. Attard G, Belldegrun AS, De Bono JS (2005) Selective blockade of androgenic steroid synthesis by novel lyase inhibitors as a therapeutic strategy for treating metastatic prostate cancer. BJU Int 96:1241–124610.1111/j.1464-410X.2005.05821.x ↗
10. Scher HI, Beer TM, Higano CS et al (2010) Antitumour activity of MDV3100 in castration-resistant prostate cancer: a phase 1–2 study. Lancet 375:1437–144610.1016/S0140-6736(10)60172-9 ↗
11. Ciccarese C, Nobili E, Grilli D, Casolari L, Rihawi K, Gelsomino F, Tortora G, Massari F (2016) The safety and efficacy of enzalutamide in the treatment of advanced prostate cancer. Expert Rev Anticancer Ther 16:681–69610.1080/14737140.2016.1192468 ↗
12. Scott LJ (2007) Abiraterone acetate: a review in metastatic castration-resistant prostrate cancer. Drugs 77:1565–157610.1007/s40265-017-0799-9 ↗
13. Haapala K, Kuukasjärvi T, Hyytinen E, Rantala I, Helin HJ, Koivisto PA (2007) Androgen receptor amplification is associated with increased cell proliferation in prostate cancer. Hum Pathol 38:474–47810.1016/j.humpath.2006.09.008 ↗
14. Edwards J, Krishna NS, Grigor KM, Bartlett JMS (2003) Androgen receptor gene amplification and protein expression in hormone refractory prostate cancer. Br J Cancer 89:552–55610.1038/sj.bjc.6601127 ↗
15. Koivisto P, Kononen J, Palmberg C et al (1997) Androgen receptor gene amplification: a possible molecular mechanism for androgen deprivation therapy failure in prostate cancer. Cancer Res 57:314–319
16. Waltering KK, Helenius MA, Sahu B, Manni V, Linja MJ, Jänne OA, Visakorpi T (2009) Increased expression of androgen receptor sensitizes prostate cancer cells to low levels of androgens. Cancer Res 69:8141–814910.1158/0008-5472.CAN-09-0919 ↗
17. Hu R, Dunn TA, Wei S et al (2009) Ligand-independent androgen receptor variants derived from splicing of cryptic exons signify hormone-refractory prostate cancer. Cancer Res 69:16–2210.1158/0008-5472.CAN-08-2764 ↗
18. Fenner A (2012) Unravelling AR splice variant signalling in CPRC. Nat Rev Urol 9:41010.1038/nrurol.2012.139 ↗
19. Nakazawa M, Antonarakis ES, Luo J (2014) Androgen receptor splice variants in the era of enzalutamide and abiraterone. Horm Cancer 5:265–27310.1007/s12672-014-0190-1 ↗
20. Guo Z, Yang X, Sun F et al (2009) A novel androgen receptor splice variant is up-regulated during prostate cancer progression and promotes androgen depletion-resistant growth. Cancer Res 69:2305–231310.1158/0008-5472.CAN-08-3795 ↗
21. Newmark JR, Hardy DO, Tonb DC, Carter BS, Epstein JI, Isaacs WB, Brown TR, Barrack ER (1992) Androgen receptor gene mutations in human prostate cancer. Proc Natl Acad Sci 89:6319–632310.1073/pnas.89.14.6319 ↗
22. Gaddipati JP, McLeod DG, Heidenberg HB, Sesterhenn IA, Finger MJ, Moul JW, Srivastava S (1994) Frequent detection of codon 877 mutation in the androgen receptor gene in advanced prostate cancers. Cancer Res 54:2861–2864
23. Wu MH, Ma WL, Hsu CL et al (2010) Androgen receptor promotes hepatitis B virus-induced hepatocarcinogenesis through modulation of hepatitis B virus RNA transcription. Sci Transl Med 2:32–35
24. Yang Z, Chang YJ, Yu IC et al (2007) ASC-J9 ameliorates spinal and bulbar muscular atrophy phenotype via degradation of androgen receptor. Nat Med 13:348–35310.1038/nm1547 ↗
25. Lai KP, Huang CK, Chang YJ et al (2013) New therapeutic approach to suppress castration-resistant prostate cancer using ASC-J9 via targeting androgen receptor in selective prostate cells. Am J Pathol 182:460–47310.1016/j.ajpath.2012.10.029 ↗
26. Miyamoto H, Yang Z, Chen YT et al (2007) Promotion of bladder cancer development and progression by androgen receptor signals. JNCI J Natl Cancer Inst 99:558–56810.1093/jnci/djk113 ↗
27. Yamashita S, Lai KP, Chuang KL et al (2012) ASC-J9 suppresses castration-resistant prostate cancer growth through degradation of full-length and splice variant androgen receptors. Neoplasia 14:74–8310.1593/neo.111436 ↗
28. Wang R, Lin W, Lin C, Li L, Sun Y, Chang C (2016) ASC-J9® suppresses castration resistant prostate cancer progression via degrading the enzalutamide-induced androgen receptor mutant AR-F876L. Cancer Lett 379:154–16010.1016/j.canlet.2016.05.018 ↗
29. Lin TH, Izumi K, Lee SO, Lin WJ, Yeh S, Chang C (2013) Anti-androgen receptor ASC-J9 versus anti-androgens MDV3100 (Enzalutamide) or Casodex (Bicalutamide) leads to opposite effects on prostate cancer metastasis via differential modulation of macrophage infiltration and STAT3-CCL2 signaling. Cell Death Dis 4:e76410.1038/cddis.2013.270 ↗
30. Lin W, Luo J, Sun Y, Lin C, Li G, Niu Y, Chang C (2018) ASC-J9 ® suppresses prostate cancer cell invasion via altering the sumoylation-phosphorylation of STAT3. Cancer Lett 425:21–3010.1016/j.canlet.2018.02.007 ↗
31. Lin TH, Lee SO, Niu Y et al (2013) Differential androgen deprivation therapies with anti-androgens casodex/bicalutamide or MDV3100/enzalutamide versus anti-androgen receptor ASC-J9® lead to promotion versus suppression of prostate cancer metastasis. J Biol Chem 288:19359–1936910.1074/jbc.M113.477216 ↗
32. Michael A, Syrigos K, Pandha H (2008) Prostate cancer chemotherapy in the era of targeted therapy. Prostate Cancer Prostatic Dis 12:13–1610.1038/pcan.2008.32 ↗
33. Tewari AK, George DJ (2013) Novel chemotherapies in development for management of castration-resistant prostate cancer. Curr Opin Urol 23:220–22910.1097/MOU.0b013e32835f7da2 ↗
34. Yuan B, Liu Y, Yu X et al (2018) FOXM1 contributes to taxane resistance by regulating UHRF1-controlled cancer cell stemness. Cell Death Dis 9:56210.1038/s41419-018-0631-9 ↗
35. Galletti E, Magnani M, Renzulli ML, Botta M (2007) Paclitaxel and docetaxel resistance: molecular mechanisms and development of new generation taxanes. ChemMedChem 2:920–94210.1002/cmdc.200600308 ↗
36. Qian DZ, Rademacher BLS, Pittsenbarger J et al (2010) CCL2 is induced by chemotherapy and protects prostate cancer cells from docetaxel-induced cytotoxicity. Prostate 70:433–44210.1002/pros.21077 ↗
37. O’Neill AJ, Prencipe M, Dowling C et al (2011) Characterisation and manipulation of docetaxel resistant prostate cancer cell lines. Mol Cancer 10:12610.1186/1476-4598-10-126 ↗
38. Luo J, Tian J, Chou F et al (2019) Targeting the androgen receptor (AR) with AR degradation enhancer ASC-J9® led to increase docetaxel sensitivity via suppressing the p21 expression. Cancer Lett 444:35–4410.1016/j.canlet.2018.09.025 ↗
39. Kang L, Gao Z, Huang W, Jin M, Wang Q (2015) Nanocarrier-mediated co-delivery of chemotherapeutic drugs and gene agents for cancer treatment. Acta Pharm Sin B 5:169–17510.1016/j.apsb.2015.03.001 ↗
40. Upponi JR, Jerajani K, Nagesha DK, Kulkarni P, Sridhar S, Ferris C, Torchilin VP (2018) Polymeric micelles: theranostic co-delivery system for poorly water-soluble drugs and contrast agents. Biomaterials 170:26–3610.1016/j.biomaterials.2018.03.054 ↗
41. Hu H, Xiao C, Wu H et al (2017) Nanocolloidosomes with selective drug release for active tumor-targeted imaging-guided photothermal/chemo combination therapy. ACS Appl Mater Interfaces 9:42225–4223810.1021/acsami.7b14796 ↗
42. Geng Y, Discher DE (2006) Visualization of degradable worm micelle breakdown in relation to drug release. Polymer 47:2519–252510.1016/j.polymer.2005.11.093 ↗
43. Devarajan PV, Jindal AB, Patil RR, Mulla F, Gaikwad RV, Samad A (2010) Particle shape: a new design parameter for passive targeting in splenotropic drug delivery. J Pharm Sci 99:2576–258110.1002/jps.22052 ↗
44. Park JH, von Maltzahn G, Zhang L et al (2009) Systematic surface engineering of magnetic nanoworms for in vivo tumor targeting. Small 5:694–70010.1002/smll.200801789 ↗
45. Decuzzi P, Ferrari M (2006) The adhesive strength of non-spherical particles mediated by specific interactions. Biomaterials 27:5307–531410.1016/j.biomaterials.2006.05.024 ↗
46. Cao S, Shao J, Xia Y et al (2019) Molecular programming of biodegradable nanoworms via ionically induced morphology switch toward asymmetric therapeutic carriers. Small 15:e190184910.1002/smll.201901849 ↗
47. Li X, He Y, Hou J, Yang G, Zhou S (2019) A time-programmed release of dual drugs from an implantable trilayer structured fiber device for synergistic treatment of breast cancer. Small. https://doi.org/10.1002/smll.20190226210.1002/smll.201902262 ↗
48. Gould S, Scott RC (2005) 2-Hydroxypropyl-β-cyclodextrin (HP-β-CD): a toxicology review. Food Chem Toxicol 43:1451–145910.1016/j.fct.2005.03.007 ↗
49. Schenk T, Stengel S, Zelent A (2014) Unlocking the potential of retinoic acid in anticancer therapy. Br J Cancer 111:2039–204510.1038/bjc.2014.412 ↗
50. Bartolini G, Ammar K, Mantovani B, Scanabissi F, Ferreri AM, Rocchi P, Orlandi M (2004) Retinoids and cancer: antitumor effect of ATRA and of a new derivative of retinoic acid, IIF, on colon carcinoma cell lines CaCo-2 and HT-29. Anticancer Res 24:1779–1783
51. Liu H, Zang C, Fenner MH, Possinger K, Elstner E (2003) PPARγ ligands and ATRA inhibit the invasion of human breast cancer cells in vitro. Breast Cancer Res Treat 79:63–7410.1023/A:1023366117157 ↗
52. Arce F, Gätjens-Boniche O, Vargas E, Valverde B, Díaz C (2005) Apoptotic events induced by naturally occurring retinoids ATRA and 13-cis retinoic acid on human hepatoma cell lines Hep3B and HepG2. Cancer Lett 229:271–28110.1016/j.canlet.2005.06.047 ↗
53. Clausen TM, Vinson PK, Minter JR, Davis HT, Talmon Y, Miller WG (1992) Viscoelastic micellar solutions: microscopy and rheology. J Phys Chem 96:474–48410.1021/j100180a086 ↗
54. Lin Z (1996) Branched worm-like micelles and their networks. Langmuir 12:1729–173710.1021/la950570q ↗
55. Shikata T, Hirata H, Kotaka T (1988) Micelle formation of detergent molecules in aqueous media. 2. Role of free salicylate ions on viscoelastic properties of aqueous cetyltrimethylammonium bromide-sodium salicylate solutions. Langmuir 4:354–35910.1021/la00080a019 ↗
56. Mitchell DJ, Ninham BW (1981) Micelles, vesicles and microemulsions. J Chem Soc Faraday Trans 2 Mol Chem Phys 77:601–629
57. Israelachvili JN, Mitchell DJ, Ninham BW (1976) Theory of self-assembly of hydrocarbon amphiphiles into micelles and bilayers. J Chem Soc Faraday Trans 2 Mol Chem Phys 72:1525–1568
58. Szejtli J (1998) Introduction and general overview of cyclodextrin chemistry. Chem Rev 98:1743–175410.1021/cr970022c ↗
59. Lu J, Chuan X, Zhang H, Dai W, Wang X, Wang X, Zhang Q (2014) Free paclitaxel loaded PEGylated-paclitaxel nanoparticles: preparation and comparison with other paclitaxel systems in vitro and in vivo. Int J Pharm 471:525–53510.1016/j.ijpharm.2014.05.032 ↗
60. Yang J, Gong X, Wang G (2015) Compatibility and mechanical properties of BAMO–AMMO/DIANP composites: a molecular dynamics simulation. Comput Mater Sci 102:1–610.1016/j.commatsci.2015.02.010 ↗
61. Jarho P, Urtti A, Pate DW, Suhonen P, Järvinen T (1996) Increase in aqueous solubility, stability and in vitro corneal permeability of anandamide by hydroxypropyl-β-cyclodextrin. Int J Pharm 137:209–21610.1016/0378-5173(96)04522-X ↗
62. Hu H, Wan J, Huang X, Tang Y, Xiao C, Xu H, Yang X, Li Z (2018) iRGD-decorated reduction-responsive nanoclusters for targeted drug delivery. Nanoscale 10:10514–1052710.1039/C8NR02534G ↗
63. Song Q, Wang X, Wang Y et al (2015) Reduction responsive self-assembled nanoparticles based on disulfide-linked drug-drug conjugate with high drug loading and antitumor efficacy. Mol Pharm 137:209–216
64. Chou TC (2018) The combination index (CI < 1) as the definition of synergism and of synergy claims. Synergy 7:49–5010.1016/j.synres.2018.04.001 ↗